Triptorelin

Amber-G

Brand Name(s):Decapeptyl SR

Indication:Endometriosis or fibroids

Rationale:

Considered:May-10

Review Date:Sep-22

Comments:
Prescribing for gynaecological conditions:
Licensed status:
All GnRH analogues are licensed to treat endometriosis, however only goserelin, leuprorelin and triptorelin are licensed to treat fibroids.
Drug choice:
Goserelin 3.6mg preparation is the first line choice.
Leuprorelin is the second line choice
Duration of treatment:
Maximum duration of treatment will be 6 months as per product licence.
Monitoring requirements:
No specific biochemical monitoring is required by Secondary or Primary Care
Secondary care review process:
Most patients will be reviewed after a 3 month period to evaluate response to treatment and review side effects.
Benefit is unlikely to be seen before the 3rd injection.
Transfer of prescribing:
Secondary Care will administer the initial injection, thereafter prescribing responsibility will be passed to Primary Care.
GP’s are advised to contact the Gynaecology department for further advice if they have enquiries regarding prescribing or the clinical management of these patients
Verbal communication Mr Alloub, Consultant Gynaecologist, DBH FT
January 2013
…………………………
For treatment of endometriosis: Suitable for restricted prescribing under defined conditions
The gonadorelin analogues (buserelin, goserelin, leuprorelin, nafarelin and triptorelin) are suitable for prescribing in primary care upon the advice of a specialist (or a primary care prescriber with a special interest in womens health).
Gonadorelin analogues for the treatment of endometriosis
MTRAC Verdict & Summary November 2010